Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

In response to a rising multistate outbreak of Cyclospora infections, the Centers for Disease Control and Prevention (CDC) has issued a health advisory for clinicians. This summary highlights the ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.

The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.

Targeting effective control of rheumatoid arthritis disease activity is crucial component of treatment strategy.

By neutralizing circulating dipeptidyl peptidase 3, the novel monoclonal antibody aims to reverse RAAS dysregulation and stabilize cardiovascular hemodynamics.